Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma.
The present study aimed to evaluate the growth-inhibitory effect of sulforaphane (SFN) and a traditional chemotherapy agent, 5-fluorouracil (5-Fu), against the proliferation of salivary gland adenoid cystic carcinoma high metastatic cell line (ACC-M) and low metastasis cell line (ACC-2). Furthermore, the expression of nuclear factor kappa B (NF-kappaB) which induces resistance to anticancer chemotherapeutic agents was also detected. The combination effect of SFN and 5-Fu was quantitatively determined using the method of median effect principle and the combination index. The nuclear NF-kappaB p65 expression after treatment with the SFN-5-Fu combination was also evaluated by western blot analysis. The ACC-M and ACC-2 cells exhibited relative resistant to 5-Fu. Treatment ACCs cells with SFN and 5-Fu in combination, led to synergistic inhibition on cell growth and a decreased expression in nuclear NF-kappaB p65 protein. This synergistic inhibitory effect was more significant in ACC-M cells, which is associated with the greatly decreased expression of NF-kappaB p65 (almost 5-fold) after the combination treatment. Our results demonstrate synergism between SFN and 5-Fu at higher doses against the ACC-M and ACC-2 cells, which was associated with the decreased expression of nuclear NF-kappaB p65 protein.
Wang
Xiao-Feng
XF
Department of Oral and Maxillofacial Surgery, the Second Affiliated Hospital of Harbin Medical University, PR China.
Wu
Dong-Mei
DM
Li
Bao-Xin
BX
Lu
Yan-Jie
YJ
Yang
Bao-Feng
BF
D016588:Anticarcinogenic Agents / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004338:Drug Combinations; D004357:Drug Synergism; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D017879:Isothiocyanates; D012468:Salivary Gland Neoplasms / Q000188:drug therapy*; D013454:Sulfoxides; D013861:Thiocyanates / Q000494:pharmacology*; D051996:Transcription Factor RelA / Q000378:metabolism
D016588:Anticarcinogenic Agents; D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D017879:Isothiocyanates; D013454:Sulfoxides; D013861:Thiocyanates; D051996:Transcription Factor RelA; C016766:sulforaphane; D005472:Fluorouracil